Mustang, Harvard partner on CRISPR CAR T therapies
Mustang Bio Inc. (NASDAQ:MBIO) partnered with Harvard University to develop CRISPR-Cas9-enhanced CAR T therapies targeting hematologic and solid tumor cancers.
The biotech in-licensed CRISPR-Cas9 gene editing technology from Harvard, as well as technology related to the development of off-the-shelf CAR T cells, for use in conjunction with Mustang's CAR T cell therapies...